Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 1, 2013, Pages 59-62

  Lehner, Julia ^a   Stötzer, Oliver J ^b   Fersching, Debora M I ^a   Nagel, Dorothea ^a   Holdenrieder, Stefan ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Hematology/Oncology Outpatient Center Munich   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Breast cancer; DNA integrity; Neoadjuvant chemotherapy; Plasma

Indexed keywords

ALU 115; ALU 247; CYCLOPHOSPHAMIDE; DNA FRAGMENT; DOCETAXEL; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALU SEQUENCE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; DNA INTEGRITY INDEX; HISTOPATHOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOADJUVANT THERAPY; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84871887149     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP51059     Document Type: Article

References (8)

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792. doi:10.1056/NEJMoa050518 PubMed (Pubitemid 41549890)
2. Bottini A, Berruti A, Tampellini M, Morrica B, Brunelli A, Gnocchi E, Brizzi MP, Aguggini S, Fara E, Alquati P, Dogliotti L. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Tumour Biol. 1997; 18: 301-310. doi:10.1159/000218043 PubMed (Pubitemid 27362333)
3. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11: 426-437. doi:10.1038/nrc3066 PubMed
4. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008; 1137: 180-189. doi:10.1196/annals.1448.012 PubMed
5. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006; 52: 1062-1069. doi:10.1373/clinchem.2006.068577 PubMed (Pubitemid 43794418)
6. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006; 24: 4270-4276. doi:10.1200/JCO.2006.05.9493 PubMed (Pubitemid 46630784)
7. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IeM. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003; 63: 3966-3968. PubMed (Pubitemid 36917913)
8. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61: 1659-1665. PubMed (Pubitemid 34292602)